Ronald M. Burch, MD, PhD, Chairman and Chief Executive Officer

Dr. Burch serves as Biowave's Chairman and Chief Executive Officer. Dr. Burch has worked within the pharmaceutical industry for 25 years in various aspects of discovery research, drug development, and product assessment and planning.

Dr. Burch was founder and President & CEO of AlgoRx Pharmaceuticals, raising $89 million in venture funding to progress three analgesic drugs to NDA, phase 3 and phase 2 prior to exiting in a reverse merger with Corgentech, and CEO of Cure Therapeutics, raising $5 million in venture funding. Dr. Burch has served as Chief Medical officer of Naurex, Inc. and Pacira Pharmaceuticals, and as Vice President of Scientific Evaluations and Immunotherapeutics for Purdue Pharma. Dr. Burch was CNS Therapeutic Area Team Chairman and Director of Pharmacology at Zeneca Pharmaceuticals, Director of Immunology, Bone Metabolism and in vivo Safety Pharmacology at Rhone-Poulenc Rorer Inc. and Director of Pain and Inflamation Research at Nova Pharmaceutical Corp.

Dr. Burch served as a Medical Staff Fellow at the National Institutes of Health, working in the laboratory of Julius Axelrod, Nobel Laureate. He received both his M.D. and Ph.D. in pharmacology from the Medical University of South Carolina, and BS degrees in chemistry and marine biology from the College of Charleston.

Bradford E. Siff, Founder and Chief Technology Officer

Mr. Siff is the founder of the Company and serves as Biowave's Chief Technology Officer and Vice Chairman of the Board. He led the original Research and Development efforts for the company's Deepwave, Sportswave and Homewave neuromodulation pain therapy systems. He created the company's image including all of the branding and collateral marketing materials for all of the company's products, which have won first place in a major design competition. Mr. Siff is responsible for the company's vision and will continue to focus on product design, applications, branding and market development.

Before founding Biowave, Mr. Siff joined CDI, a company that held a license to an advanced, patented, non-invasive dental electronic anesthesia system. Mr. Siff developed and managed the Company's initial test market and product introduction. He grew the company from 5 to 85 people and from $0 to $2 million in revenue. Mr. Siff developed the financial and business models and created and implemented the marketing strategy to sell dentists a non-invasive dental electronic anesthesia system that provides anesthesia without needles, numbness or chemicals. Mr. Siff managed the sales force, technical training and customer service organization and operations. He also initiated and managed U.S. clinical studies of the dental device. Mr. Siff helped to dramatically improve the quality and performance of the device in conjunction with the Company's contract manufacturer, and performed FDA QSR audits to ensure proper record keeping in accordance with FDA Quality System regulations.

Before joining CDI, Mr. Siff was Vice President, Mergers & Acquisitions for Daiwa Securities America, Inc. During his seven year tenure at Daiwa, he was responsible for new business generation and directing technology and medical device related mergers, acquisitions and strategic advisory transactions for Daiwa.

Mr. Siff holds an MBA degree from the Samuel C. Johnson Graduate School of Management at Cornell University. He holds a Masters of Engineering and was awarded a teaching fellowship from Cornell University's Graduate School of Operations Research and Information Engineering (OR & IE), and he received a Bachelor of Science degree in Mechanical Engineering from Cornell.

David W. Kratovil, Chief Operating Officer

Mr. Kratovil serves as Biowave’s Chief Operating Officer and is responsible for market development, sales, marketing, distribution and customer service and satisfaction. Since 2007, Mr. Kratovil has been a consultant to the Company’s Board and management.

In 2004, Mr. Kratovil co-founded KN Associates, LLC in Greenwich, CT. KN was a Merchant Banking and Corporate Advisory firm providing Strategic, Corporate and Business Development advice and plans. In addition, KN advised investors in the origination and structuring of investment opportunities with emerging companies. KN’s business activities were principally focused within the industry verticals of Healthcare, Information Technology and Alternate Energy.

Prior to forming KN, Mr. Kratovil held positions within the Corporate and Investment Banking and Market Trading Divisions of Credit Suisse First Boston and Credit Suisse providing clients with domestic and international capital markets and precious metals marketing and trading strategies. Mr. Kratovil began his career at Chemical Bank which is now JP Morgan Chase in New York City.

A graduate of the University of Virginia, Mr. Kratovil has completed executive programs at the University of Virginia and Harvard University.

John N. Carter, Ph.D., Director of Research & Development

Dr. Carter serves as Director of Research & Development for the company and is responsible for the development of the Biowave technology. Dr. Carter is an Assistant Professor in the Department of Medicine at The Weill College of Medicine and Medical Sciences of Cornell University-New York Presbyterian Hospital, New York City. His research is specifically focused on image processing, biological and physiological parameter sensor development, specialized computer system design, quantitative radiology and the mechanics and molecular biology of heart failure.

Dr. Carter also serves as Assistant Professor of Chemical Engineering at Cornell University, focusing on the chemistry of gas phase and gas/solid phase metal-organic/hydride reactions involving non-thermal energy sources, organic/inorganic materials, molecular self-assembly, sensors, electronic device characterization, process control and measurement. Between 1991 and 1994, Dr. Carter served as Assistant Research Professor in the Department of Chemistry at Polytechnic University. His research was in the ultrasonic monitoring of crystal growth during directional solidification, ferroelectric thin film deposition and process control systems. From 1988 through 1991, Dr. Carter worked as a part-time Post. Doc. Fellow, in the Department of Chemistry at Polytechnic University studying Group III/V and Group II/VI materials growth and laser-assisted chemistry. Dr. Carter has over 23 published research papers involving various diagnostic and therapeutic applications of electronic medical devices as they relate to the human body. He also is an active member in numerous scientific, medical and engineering societies.

Dr. Carter holds a Ph.D. in Chemical Physics and a B.S. in Physics with a minor in Electrical and Computer Engineering. Dr. Carter won an award for the Outstanding Bioengineering Project. Both his degrees are from Polytechnic University in Brooklyn, New York.

Mike J. Stout, R.Ph., Director of Technical Marketing and Sales

Mr. Stout serves as Biowave's Director of Technical Marketing and Sales. Prior to joining Biowave, he founded Revolution Medical, a consulting service for small and startup medical device companies in the markets of ambulatory drug delivery, pain management and regional anesthesia.

During the ten years prior, Mr. Stout held sales and marketing director positions for Sorenson Medical, and Algos, LC; both pioneers in the localized delivery of medication for post-operative pain management. He was instrumental in the development of the MicroJect PCA, PCEA and AmBit line of ambulatory infusion pumps. Mr. Stout was one of the original founders of Algos which was subsequently acquired by McKinley Medical LLC where he served as Director of Technical Marketing and Business Development. Mr. Stout was a recipient of the Outstanding Design Team award from MDDI Magazine, June 2005, for his part in the development of the AmBit ambulatory infusion pump. During the previous eight years Mr. Stout served as Director of Pharmacy for the high-tech home intravenous therapy pharmacies Omnicus and Quantum Health Resources. While at Omnicus, he published a method for electrolyte pooling in the compounding of home intravenous feeding solutions. During his tenure at Quantum, he was recognized for a significant improvement in operational efficiency by achieving the highest return on investment of all company branches and doubling capacity in 2 years.

Mr. Stout received his B.S. in Pharmacy from the University of Utah. He has lectured both domestically and internationally on various infusion therapy topics including pain management.